The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The
https://
ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
Share
1
Department of Gynecologic Endocrinology and Reproductive Medicine, the Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.
2
Department of Women's Health, Affiliated Maternity and Child Health Care Hospital of Nantong University, Nantong 226001, China.
3
Department of Gynecology, Shanghai Jing'an Central Hospital of Fudan University, Shanghai 200040, China.
1
Department of Gynecologic Endocrinology and Reproductive Medicine, the Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.
2
Department of Women's Health, Affiliated Maternity and Child Health Care Hospital of Nantong University, Nantong 226001, China.
3
Department of Gynecology, Shanghai Jing'an Central Hospital of Fudan University, Shanghai 200040, China.
Objective:
To explore the clinical and biochemical discriminants of hyperandrogenism in functional hypothalamic amenorrhea (FHA).
Methods:
From January to September 2022, a total of 56 patients with FHA group in the Obstetrics and Gynecology Hospital of Fudan University outpatient clinic were included in this retrospective cross-sectional analysis. According to the clinical or biochemical features of hyperandrogenism, FHA patients can be divided into two subgroups, namely hyperandrogenic FHA and non-hyperandrogenic FHA. Explore the differences and its significances between hyperandrogenic FHA and non-hyperandrogenic FHA by comparing anthropometry, reproductive hormones, AMH, ultrasonic manifestation, the scores of eating attitude test, depression questionnaire and anxiety scale respectively and analyzing their correlations.
Results:
The age of 56 FHA patients was 15-32(23.36±4.90) years, and body mass index(BMI) was (18.91±2.49) kg/m
2
. The age of hyperandrogenic FHA and non-hyperandrogenic FHA was (21.76±4.40) and (24.05±5.00) (
P
=0.109) years old respectively, and BMI was (19.14±3.15 )and (18.81±2.18) kg/m
2
(
P
=0.702). Compared to the non-hyperandrogenic FHA, the AMH (6.46 and 3.63 ng/ml,
P
=0.025) and PRL (278.78 and 149.46 mU/ml,
P
=0.002) levels were higher in hyperandrogenic FHA group. There was no significant difference between the hyperandrogenic and non-hyperandrogenic FHA group in body composition.GAD-7 (
r
=0.455,
P
=0.005) and PHQ-9 (
r
=0.664,
P
<0.001) were correlated with EAT-26 scores in non-hyperandrogenic FHA group, but no significant correlation was shown between PHQ-9 (
r
=0.091,
P
=0.766)、GAD-7 (
r
=0.304,
P
=0.313) and EAT-26 in hyperandrogenic FHA group.
Conclusions:
Some patients with FHA had clinical manifestations of hyperandrogenism and mildly elevated AMH and PRL, with underlying PCOS endocrine characteristics.
目的：
探究功能性下丘脑性闭经（FHA）合并雄激素过多患者的临床特征。
方法：
回顾性分析2022年1—9月在复旦大学附属妇产科医院就诊的56例FHA患者，根据FHA初诊时是否具有雄激素过多的临床或生化表现，分为高雄激素组（17例）和非高雄激素组（39例）。比较高雄激素和非高雄激素组之间在人体测量学、生殖激素、抗米勒管激素（AMH）、超声表现、进食态度问卷和情绪量表之间的差异及各项指标与问卷量表分数相关性。
结果：
56例FHA患者的年龄为15~32（23.36±4.90）岁，体质指数（BMI）为（18.91±2.49）kg/m
2
。高雄激素组和非高雄激素组患者年龄分别为（21.76±4.40）和（24.05±5.00）岁（
P
=0.109），BMI分别为（19.14±3.15）和（18.81±2.18）kg/m
2
（
P
=0.702）。39.3%（22例）的FHA患者有暴食经历，体脂不足者约占51.8%（29例），骨骼肌量不足者占53.6%（30例）。相比非高雄激素组，高雄激素组AMH（6.46比3.63 ng/ml，
P
=0.025）和催乳素（PRL）（278.78比149.46 mU/ml，
P
=0.002）更高。非高雄激素组广泛焦虑障碍量表（GAD-7）（
r
=0.455，
P
=0.005）、应用抑郁自评量表（PHQ-9）（
r
=0.664，
P
<0.001）评分均与进食态度自评问卷（EAT-26）评分相关，高雄激素FHA组中PHQ-9（
r
=0.091，
P
=0.766）和GAD-7（
r
=0.304，
P
=0.313）与EAT-26无相关性。
结论：
部分FHA患者具有高雄激素临床表现，且存在AMH和PRL轻度升高、潜在多囊卵巢综合征（PCOS）的内分泌特征。.
Carmina E, et al.
Gynecol Endocrinol. 2018 Apr;34(4):301-304. doi: 10.1080/09513590.2017.1395842. Epub 2017 Oct 27.
Gynecol Endocrinol. 2018.
PMID:
29073797
Javed A, et al.
Int J Womens Health. 2015 Jan 13;7:103-11. doi: 10.2147/IJWH.S73011. eCollection 2015.
Int J Womens Health. 2015.
PMID:
25610004
Free PMC article.
Pasquali R, et al.
J Clin Endocrinol Metab. 2016 May;101(5):2013-22. doi: 10.1210/jc.2015-4009. Epub 2016 Mar 10.
J Clin Endocrinol Metab. 2016.
PMID:
26964728
Phylactou M, et al.
Clin Endocrinol (Oxf). 2021 Aug;95(2):239-252. doi: 10.1111/cen.14402. Epub 2021 Jan 19.
Clin Endocrinol (Oxf). 2021.
PMID:
33354766
Review.
Goudas VT, et al.
Endocrinol Metab Clin North Am. 1997 Dec;26(4):893-912. doi: 10.1016/s0889-8529(05)70286-3.
Endocrinol Metab Clin North Am. 1997.
PMID:
9429864
Review.
